MarketPulse

metabolic disorders

2 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.
AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment